Literature DB >> 6528335

Role of lipid A in the production of tumor necrosis factor and differences in antitumor activity between tumor necrosis factor and lipopolysaccharide.

K Haranaka, N Satomi, A Sakurai, O Kunii.   

Abstract

The role of lipopolysaccharide (LPS) in the production of tumor necrosis factor (TNF) was examined. Alkaline treatment of LPS greatly reduced the TNF-producing activity of LPS, but TNF was produced when a large amount was injected. Free lipid A and lipid A-mouse serum albumin complex, which were prepared from the acid hydrolyzate, effectively induced TNF. However, the polysaccharide-rich fraction of the acid hydrolyzate was not capable of inducing TNF. Preincubation of LPS with polymixin B largely abrogated the TNF-producing activity of LPS. The differences in antitumor activity between TNF and LPS were also tested. TNF has a direct cytotoxicity against cancer cells in vitro but LPS does not. The activity of TNF was not inhibited by preincubation with polymixin B. Tumor necrosis in vivo was inhibited by preincubation of LPS with polymixin B but not by that of TNF. Galactosamine was found to induce susceptibility to the lethal effects of LPS, but did not influence the action of TNF. Lipid A is largely responsible for the TNF-inducing activity of LPS, but is not essential for the antitumor activity of TNF.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6528335     DOI: 10.1620/tjem.144.385

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  9 in total

1.  Optimal induction of tumor necrosis factor production in human monocytes requires complete S-form lipopolysaccharide.

Authors:  D N Männel; W Falk
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

2.  Sendai virus induces high levels of tumor necrosis factor mRNA in human peripheral blood leukocytes.

Authors:  S L Berent; R M Torczynski; A P Bollon
Journal:  Nucleic Acids Res       Date:  1986-11-25       Impact factor: 16.971

3.  Lipid A-mediated tolerance and cancer therapy.

Authors:  Cheryl E Rockwell; David C Morrison; Nilofer Qureshi
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

4.  Therapeutic ratio of mono or combination bacterial lipopolysaccharide therapy in methylnitrosourea-induced rat mammary carcinoma.

Authors:  M R Berger; E Petru; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

5.  Purification, characterization, and antitumor activity of nonrecombinant mouse tumor necrosis factor.

Authors:  K Haranaka; E A Carswell; B D Williamson; J S Prendergast; N Satomi; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

6.  Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs.

Authors:  K Haranaka; N Satomi; A Sakurai; R Haranaka; N Okada; M Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Role of first stimulating agents in the production of tumor necrosis factor.

Authors:  K Haranaka; N Satomi; A Sakurai; R Haranaka
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

8.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

9.  Molecular mechanism of macrophage activation by red ginseng acidic polysaccharide from Korean red ginseng.

Authors:  Se Eun Byeon; Jaehwi Lee; Ji Hye Kim; Woo Seok Yang; Yi-Seong Kwak; Sun Young Kim; Eui Su Choung; Man Hee Rhee; Jae Youl Cho
Journal:  Mediators Inflamm       Date:  2012-02-01       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.